JPH08500845A - 細胞分裂促進及び細胞運動促進のペプチド阻害剤 - Google Patents
細胞分裂促進及び細胞運動促進のペプチド阻害剤Info
- Publication number
- JPH08500845A JPH08500845A JP6521434A JP52143494A JPH08500845A JP H08500845 A JPH08500845 A JP H08500845A JP 6521434 A JP6521434 A JP 6521434A JP 52143494 A JP52143494 A JP 52143494A JP H08500845 A JPH08500845 A JP H08500845A
- Authority
- JP
- Japan
- Prior art keywords
- val
- tyr
- receptor
- phosphorylated
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.ヒト肝細胞成長因子レセプターの細胞内領域の一部の配列を有しており、シ トソールシグナルトランスデューサーと結合することが可能なペプチド。 2.ホスファチジルイノシトール3−キナーゼのp85サブユニットと活性化肝 細胞成長因子レセプターとの結合を阻害することが可能な請求項1に記載のペプ チド。 3.Shcタンパク質と活性化肝細胞成長因子レセプターとの結合を阻害するこ とが可能な請求項1に記載のペプチド。 4.Shcタンパク質とシトソールシグナルトランスデューサーとの結合を阻害 することが可能な請求項1に記載のペプチド。 5.Shcタンパク質の一部の配列を有しており、シトソールシグナルトランス デューサーと結合することが可能なペプチド。 6.Shcタンパク質とGrb2タンパク質との結合を阻害することが可能な請 求項5に記載のペプチド。 7.Grb2タンパク質と活性化肝細胞成長因子レセプターとの結合を阻害する ことが可能な請求項5に記載のペプ チド。 8.配列XN−YVN(又はH)V−Xc(式中、XN及びXcは各々0〜16ア ミノ酸の配列である)を有する請求項1から7のいずれか一項に記載のペプチド 。 9.XN及びXcがHGF/SFレセプター及びShcタンパク質においてYVN (又はH)V配列の一方を取り囲む配列である請求項8に記載のペプチド。 10.H−Asp−Asp−Pro−Ser−Tyr*−Val−Asn−Va l−Gln−OH(式中、Tyr*はリン酸化又は非リン酸化チロシン残基であ る)である請求項9に記載のペプチド。 11.H−Val−Asn−Ala−Thr−Tyr*−Val−Asn−Va l−Lys−OH(式中、Tyr*はリン酸化又は非リン酸化チロシン残基であ る)である請求項9に記載のペプチド。 12.H−Ile−Gly−Glu−His−Tyr*−Val−His−Va l−Asn−OH(式中、Tyr*はリン酸化又は非リン酸化チロシン残基であ る)である請求項9に記載のペプチド。 13.H−Ile−Gly−Glu−His−Tyr*− Val−His−Val−Asn−Ala−Thr−Tyr*−Val−Asn −Val−Lys−OH(式中、Tyr*はリン酸化又は非リン酸化チロシン残 基である)である請求項9に記載のペプチド。 14.H−Tyr*−Val−His−Val−Asn−Ala−Thr−Ty r−OH(式中、Tyr*はリン酸化又は非リン酸化チロシン残基である)であ る請求項9に記載のペプチド。 15.H−Tyr*−Val−His−Val−Asn−Ala−Thr−Ty r*−Val−Asn−Val−Lys−OH(式中、Tyr*はリン酸化又は 非リン酸化チロシン残基である)である請求項9に記載のペプチド。 16.H−Tyr*−Val−Asn−Val−Lys−Cys−Val−Al a−OH(式中、Tyr*はリン酸化又は非リン酸化チロシン残基である)であ る請求項9に記載のペプチド。 17. (式中、Tyr*はリン酸化又は非リン酸化チロシン残基である)である請求項 1に記載のペプチド。 18.単一アミノ酸及び/又は2個以上のアミノ酸残基から予備形成されたペプ チドからペプチドを化学的に合成することからなる、請求項1から17のいずれ か一項に記載のペプチドの製造方法。 19.予備リン酸化保護チロシン残基を固相合成中に直接導入する請求項18に 記載の方法。 20.ペプチドを固体支持体に結合しながら予備形成保護ペプチドのチロシン残 基をリン酸化する請求項18に記載の方法。 21.医薬的に許容可能なキャリヤー又は希釈剤と、活性成分として請求項1か ら17のいずれか一項に記載のペプチドを含有する医薬組成物。 22.ヒト又は動物身体の治療に用いる請求項1から17のいずれか一項に記載 のペプチド。 23.新生物疾患の治療に用いる請求項22に記載のペプチド。 24.新生物疾患の治療用医薬の製造における請求項1から17のいずれか一項 に記載のペプチドの使用。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9313528.3 | 1993-06-30 | ||
GB939313528A GB9313528D0 (en) | 1993-06-30 | 1993-06-30 | Peptide inhibitors of mitogenesis and motogenesis |
GB9407673.4 | 1994-04-18 | ||
GB9407673A GB9407673D0 (en) | 1994-04-18 | 1994-04-18 | Peptide inhibitors of mitogenesis and motogenius |
PCT/EP1994/001943 WO1995001376A1 (en) | 1993-06-30 | 1994-06-15 | Peptide inhibitors of mitogenesis and motogenesis |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH08500845A true JPH08500845A (ja) | 1996-01-30 |
JP3585044B2 JP3585044B2 (ja) | 2004-11-04 |
Family
ID=26303150
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52143494A Expired - Fee Related JP3585044B2 (ja) | 1993-06-30 | 1994-06-15 | 細胞分裂促進及び細胞運動促進のペプチド阻害剤 |
Country Status (15)
Country | Link |
---|---|
US (2) | US5594105A (ja) |
EP (1) | EP0662090A1 (ja) |
JP (1) | JP3585044B2 (ja) |
KR (1) | KR950703003A (ja) |
CN (1) | CN1056153C (ja) |
AU (1) | AU670704B2 (ja) |
CA (1) | CA2142713A1 (ja) |
FI (1) | FI950729A (ja) |
HU (1) | HU219813B (ja) |
IL (1) | IL110160A (ja) |
MY (1) | MY130026A (ja) |
NZ (1) | NZ268006A (ja) |
PL (1) | PL179628B1 (ja) |
RU (1) | RU2146262C1 (ja) |
WO (1) | WO1995001376A1 (ja) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0804218A1 (en) * | 1994-03-17 | 1997-11-05 | National Jewish Center For Immunology And Respiratory Medicine | Product and process for regulating signal transduction pathways |
US5744313A (en) * | 1994-12-09 | 1998-04-28 | The Regents Of The University Of California | Assay employing novel protein domain which binds tyrosine phosphorylated proteins |
US5807989A (en) * | 1994-12-23 | 1998-09-15 | New York University | Methods for treatment or diagnosis of diseases or disorders associated with an APB domain |
US6107457A (en) * | 1995-02-16 | 2000-08-22 | Board Of Regents, The University Of Texas System | Bcr-Abl directed compositions and uses for inhibiting Philadelphia chromosome stimulated cell growth |
US6214344B1 (en) | 1995-06-02 | 2001-04-10 | Genetech, Inc. | Hepatocyte growth factor receptor antagonists and uses thereof |
US5686292A (en) | 1995-06-02 | 1997-11-11 | Genentech, Inc. | Hepatocyte growth factor receptor antagonist antibodies and uses thereof |
US5646036A (en) * | 1995-06-02 | 1997-07-08 | Genentech, Inc. | Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies |
GB9603227D0 (en) * | 1996-02-15 | 1996-04-17 | Pharmacia Spa | Peptide antagonists of cellular mitogenesis and motogenesis and their therapeutic use |
CA2343934A1 (en) | 1998-09-25 | 2000-04-06 | The Children's Medical Center Corporation | Short peptides which selectively modulate the activity of protein kinases |
US7226991B1 (en) * | 1999-03-23 | 2007-06-05 | United States Of America, Represented By The Secretary, Department Of Health And Human Services | Phenylalanine derivatives |
JP4604161B2 (ja) * | 1999-03-23 | 2010-12-22 | アメリカ合衆国 | フェニルアラニン誘導体 |
IL131142A0 (en) * | 1999-07-28 | 2001-01-28 | Rad Ramot | Prognosis of breast cancer and other diseases |
US7871981B2 (en) * | 1999-10-22 | 2011-01-18 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibition of cell motility, angiogenesis, and metastasis |
DE60034959T2 (de) | 1999-10-22 | 2008-01-17 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Hemmung der zellmotilität und angiogenese mit grb2 sh2-domäne inhibitoren |
AU2625201A (en) | 2000-01-03 | 2001-07-16 | Ramot University Authority For Applied Research And Industrial Development Ltd. | Glycogen synthase kinase-3 inhibitors |
EP1383792A2 (en) * | 2000-08-22 | 2004-01-28 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Sh2 domain binding inhibitors |
US7425537B2 (en) * | 2000-08-22 | 2008-09-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | SH2 domain binding inhibitors |
US7378432B2 (en) | 2001-09-14 | 2008-05-27 | Tel Aviv University Future Technology Development L.P. | Glycogen synthase kinase-3 inhibitors |
AU2003228225B2 (en) * | 2002-03-01 | 2010-05-13 | Roger Williams Hospital | SHC protein-related methods and compositions for the prognosis of breast, prostate and ovarian cancer |
US20050004008A1 (en) * | 2002-03-01 | 2005-01-06 | Frackelton A. Raymond | SHC proteins as therapeutic targets in proliferative diseases |
JP2006514104A (ja) | 2002-12-12 | 2006-04-27 | テル アヴィヴ ユニヴァーシティ フューチャー テクノロジー ディヴェロップメント エル.ピー. | グリコーゲンシンターゼキナーゼ−3阻害剤 |
US20040138104A1 (en) * | 2003-01-14 | 2004-07-15 | The Government Of The United States Of America Represented By The Secretary, | Peptides |
WO2004094463A2 (en) * | 2003-04-18 | 2004-11-04 | University Of Florida Research Foundation, Inc. | Peptide inhibitors of autophosphorylation protein kinases |
US20050119163A1 (en) * | 2003-09-18 | 2005-06-02 | The Government Of The United States Of America, As Represented By The Secretary, | SH2 domain binding inhibitors |
AU2005267720B2 (en) | 2004-08-05 | 2012-02-23 | Genentech, Inc. | Humanized anti-cmet antagonists |
SG161281A1 (en) | 2005-04-15 | 2010-05-27 | Genentech Inc | Hgf beta chain variants |
WO2007058965A1 (en) * | 2005-11-11 | 2007-05-24 | Roger Williams Hospital | P66-shc as predictive marker in cancer treatment |
US20090054366A1 (en) * | 2007-06-15 | 2009-02-26 | Reliance Life Sciences Pvt. Ltd. | RNAi MEDIATED KNOCKDOWN OF NUMA FOR CANCER THERAPY |
US9802993B2 (en) * | 2007-10-15 | 2017-10-31 | Chugai Seiyaku Kabushiki Kaisha | Method for producing a cell for protein production by treating a cell overexpressing a taurine transporter with methotrexate |
IT1397873B1 (it) * | 2008-09-30 | 2013-02-04 | Multimedica Holding S P A | Uso di peptidi nella terapia antiangiogenica relativa a patologie tumorali |
IT1397874B1 (it) * | 2008-09-30 | 2013-02-04 | Multimedica Holding S P A | Uso di peptidi nella terapia antiangiogenica |
US20130004484A1 (en) | 2011-06-30 | 2013-01-03 | Genentech, Inc. | Anti-c-met antibody formulations |
RU2016141385A (ru) | 2014-03-24 | 2018-04-28 | Дженентек, Инк. | Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf |
CN105601710B (zh) * | 2014-05-29 | 2019-10-15 | 李宝军 | 一种治疗癌症的肽变体及其应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5362716A (en) * | 1989-12-27 | 1994-11-08 | The United States Of America As Represented By The Department Of Health And Human Services | Methods for stimulating hematopoietic progenitors using hepatocyte growth factor and lymphokines |
EP0584125B1 (en) * | 1991-05-10 | 1997-07-16 | PHARMACIA & UPJOHN S.p.A. | Truncated forms of the hepatocyte growth factor (hgf) receptor |
DE4136443A1 (de) * | 1991-11-06 | 1993-05-13 | Boehringer Ingelheim Int | Expression der reifen proteinase 2a, ihre partielle reinigung und bereitstellung kompetitiv wirkender substrate |
US7642971B2 (en) * | 2007-05-25 | 2010-01-05 | Sony Ericsson Mobile Communications Ab | Compact diversity antenna arrangement |
-
1994
- 1994-06-15 RU RU95108385A patent/RU2146262C1/ru active
- 1994-06-15 NZ NZ268006A patent/NZ268006A/en unknown
- 1994-06-15 AU AU70718/94A patent/AU670704B2/en not_active Ceased
- 1994-06-15 KR KR1019950700794A patent/KR950703003A/ko not_active Application Discontinuation
- 1994-06-15 EP EP94919632A patent/EP0662090A1/en not_active Withdrawn
- 1994-06-15 HU HU9500919A patent/HU219813B/hu not_active IP Right Cessation
- 1994-06-15 CN CN94190440A patent/CN1056153C/zh not_active Expired - Fee Related
- 1994-06-15 CA CA002142713A patent/CA2142713A1/en not_active Abandoned
- 1994-06-15 WO PCT/EP1994/001943 patent/WO1995001376A1/en not_active Application Discontinuation
- 1994-06-15 PL PL94307742A patent/PL179628B1/pl unknown
- 1994-06-15 JP JP52143494A patent/JP3585044B2/ja not_active Expired - Fee Related
- 1994-06-27 US US08/266,514 patent/US5594105A/en not_active Expired - Fee Related
- 1994-06-29 IL IL11016094A patent/IL110160A/xx not_active IP Right Cessation
- 1994-06-30 MY MYPI94001711A patent/MY130026A/en unknown
-
1995
- 1995-02-17 FI FI950729A patent/FI950729A/fi unknown
-
1996
- 1996-05-29 US US08/654,604 patent/US5912183A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
MY130026A (en) | 2007-05-31 |
RU2146262C1 (ru) | 2000-03-10 |
WO1995001376A1 (en) | 1995-01-12 |
EP0662090A1 (en) | 1995-07-12 |
HUT71324A (en) | 1995-11-28 |
RU95108385A (ru) | 1997-03-20 |
AU670704B2 (en) | 1996-07-25 |
PL179628B1 (pl) | 2000-10-31 |
FI950729A (fi) | 1995-04-19 |
CN1056153C (zh) | 2000-09-06 |
FI950729A0 (fi) | 1995-02-17 |
CA2142713A1 (en) | 1995-01-12 |
US5912183A (en) | 1999-06-15 |
NZ268006A (en) | 1996-09-25 |
HU219813B (hu) | 2001-08-28 |
AU7071894A (en) | 1995-01-24 |
IL110160A (en) | 2000-06-29 |
JP3585044B2 (ja) | 2004-11-04 |
HU9500919D0 (en) | 1995-05-29 |
US5594105A (en) | 1997-01-14 |
KR950703003A (ko) | 1995-08-23 |
CN1111455A (zh) | 1995-11-08 |
PL307742A1 (en) | 1995-06-12 |
IL110160A0 (en) | 1994-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH08500845A (ja) | 細胞分裂促進及び細胞運動促進のペプチド阻害剤 | |
US5916755A (en) | Methods of characterizing ligands for the erbB-3 receptor, methods of influencing erbB-3 activities and methods of diagnosing erbB-3-related neoplasm | |
Mori et al. | Identification of two juxtamembrane autophosphorylation sites in the PDGF beta‐receptor; involvement in the interaction with Src family tyrosine kinases. | |
Ponzetto et al. | A novel recognition motif for phosphatidylinositol 3-kinase binding mediates its association with the hepatocyte growth factor/scatter factor receptor | |
HU215581B (hu) | Eljárás fibroblaszt növekedési faktor receptorok előállítására és terápiás alkalmazására | |
US20070178527A1 (en) | Human platelet-derived growth factor receptors | |
US6280964B1 (en) | Binding sites for phosphotyrosine binding domains | |
CA2564538A1 (en) | Compositions and methods for modulating signaling mediated by igf-1 receptor and erbb receptors | |
US5863888A (en) | Human Bek Fibroblast growth factor receptor | |
US8703917B2 (en) | Epidermal growth factor receptor variants and pharmaceutical compositions thereof | |
WO2011140391A2 (en) | Egfr-related polypeptides and methods of use | |
EP0811686A2 (en) | Human platelet-derived growth factor receptors | |
WO2009137837A2 (en) | Neuregulin/erbb signaling and integrin | |
US7276587B2 (en) | Antibodies to EGFH2 polypeptides | |
US20080026992A1 (en) | Tyrosine Phosphorylation of Cdk Inhibitor Proteins of the Cip/Kip Family | |
US8741292B2 (en) | Proteins and methods for modulating cell activity | |
US20030105287A1 (en) | Inhibition of the proliferation of cells of the multiple myeloma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20031112 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040105 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040210 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A133 Effective date: 20040604 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040604 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20040713 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20040729 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20070813 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080813 Year of fee payment: 4 |
|
LAPS | Cancellation because of no payment of annual fees |